The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 1,012
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 135
Self-citationPrediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
Vos, S. J. B., van Rossum, I. A., Verhey, F. R. J., Knol, D. L., Soininen, H. S., Wahlund, L., Hampel, H. J., Tsolaki, M., Minthon, L., Frisoni, G. B., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318288690c · Cited by 140
Self-citationSabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B. R., & Sperling, R. A. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 134
Macchia, E., Romele, P., Manoli, K., Ghittorelli, M., Magliulo, M., Kovacs-Vajna, Z. M., Torricelli, F., & Torsi, L. (2018) · Flexible and Printed Electronics · doi:10.1088/2058-8585/aad0cb · Cited by 133
Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 148
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
The critical need for defining preclinical biomarkers in Alzheimer's disease
Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.015 · Cited by 138
Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease
Ewers, M., Insel, P. S., Stern, Y., Weiner, M. W., & Initiative, A. D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e31828970c2 · Cited by 138
Self-citationCerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
Associations between [ 18 F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample
La Joie, R., Bejanin, A., Fagan, A. M., Ayakta, N., Baker, S. L., Bourakova, V., Boxer, A. L., Cha, J., Karydas, A., Jerome, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004860 · Cited by 141
Toledo, J. B., Toledo, E., Weiner, M. W., Jack, C. R., Jagust, W., Lee, V. M. ‐., Shaw, L. M. J., & Trojanowski, J. Q. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.08.008 · Cited by 130
Self-citationTrzepacz, P. T., Yu, P., Sun, J., Schuh, K. J., Case, M. G., Witte, M. M., Hochstetler, H. M., & Hake, A. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.018 · Cited by 131
Single-Molecule Arrays for Protein and Nucleic Acid Analysis
Cohen, L., & Walt, D. R. (2017) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-061516-045340 · Cited by 137
Hey, J. A., Yu, Y., Versavel, M., Abushakra, S. R., Kočiš, P., Power, A., Kaplan, P. L., Amedio, J. C., & Tolar, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 132
Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 136
Self-citationPaterson, R. W., Slattery, C. F., Poole, T., Nicholas, J. M., Magdalinou, N. K., Toombs, J., Chapman, M. D., Lunn, M. P., Heslegrave, A., Foiani, M. S., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0361-3 · Cited by 130
Self-citationYang, T., Hong, S. Y., O’Malley, T. T., Sperling, R. A., Walsh, D. M., & Selkoe, D. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.005 · Cited by 122
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases
Coughlin, D. G., Hurtig, H. I., & Irwin, D. J. (2019) · Movement Disorders · doi:10.1002/mds.27867 · Cited by 132
Cruchaga, C., Del‐Aguila, J. L., Saef, B., Black, K., Fernandez, M. V., Budde, J., Ibanez, L., Deming, Y., Kapoor, M., Tosto, G., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.013 · Cited by 138
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
Landau, S. M., Horng, A., Fero, A., Jagust, W. J., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., Aisen, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002576 · Cited by 128
Self-citationPrediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data
Li, K., Chan, W., Doody, R. S., Quinn, J., Luo, S., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161201 · Cited by 126
Lee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125
Extracellular Vesicle as a Source of Alzheimer’s Biomarkers: Opportunities and Challenges
Lee, S., Mankhong, S., & Kang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071728 · Cited by 129
CSF biomarkers for Alzheimer's disease: current utility and potential future use
Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 124
Ritchie, C. W., & Ritchie, K. A. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001893 · Cited by 124
Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123
Self-citationMulder, E. R., de Jong, R. A., Knol, D. L., van Schijndel, R. A., Cover, K. S., Visser, P. J., Barkhof, F., & Vrenken, H. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.01.058 · Cited by 122
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 122
Alosco, M. L., Tripodis, Y., Fritts, N. G., Heslegrave, A., Baugh, C. M., Conneely, S. E., Mariani, M. L., Martin, B. M., Frank, S., Mez, J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.004 · Cited by 126
Self-citationBasher, A., Kim, B. C., Lee, K. H., & Jung, H. Y. (2021) · IEEE Access · doi:10.1109/access.2021.3059658 · Cited by 130
Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 127
Self-citationHonarvar, N. M., Saedisomeolia, A., Abdolahi, M., Shayeganrad, A., Sangsari, G. T., Rad, B. H., & Muench, G. W. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0857-x · Cited by 123
Prevalence of preclinical Alzheimer disease
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Wærn, M., Höglund, K., Andréasson, U., Wetterberg, H., Börjesson‐Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 123
Self-citationByun, M. S., Kim, S. E., Park, J., Yi, D., Choe, Y. M., Sohn, B. K., Choi, H. J., Baek, H., Han, J., Woo, J. I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142756 · Cited by 121
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes
Beckett, L. A., Harvey, D. J., Gamst, A. C., Donohue, M., Kornak, J., Zhang, H., Kuo, J. H., & Initiative, A. D. N. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.002 · Cited by 121
Self-citationPereira, J. B., Westman, E., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.002 · Cited by 120
Baldeiras, I., Santana, I. J., Leitão, M. J., Gens, H., Pascoal, R., Tábuas‐Pereira, M., Beato-Coelho, J., Duro, D., Almeida, M. R., & Oliveira, C. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0362-2 · Cited by 123
Winston, C. N., Goetzl, E. J., Schwartz, J. B., Elahi, F. M., & Rissman, R. A. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.11.002 · Cited by 120
Serial MRI and CSF biomarkers in normal aging, MCI, and AD
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154
Self-citationPRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 117
Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Roddey, J. C., Blennow, K., Aisen, P. S. S., Brewer, J. B., Hyman, B. T., & Dale, A. M. (2011) · Annals of Neurology · doi:10.1002/ana.22509 · Cited by 118
Self-citationReduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
Self-citationThe keystone of Alzheimer pathogenesis might be sought in Aβ physiology
Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116
Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116
Chen, Z., Mengel, D., Keshavan, A., Rissman, R. A., Billinton, A., Perkinton, M. S., Percival‐Alwyn, J., Schultz, A. P., Properzi, M. J., Johnson, K. A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.010 · Cited by 114
A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease
Olazarán, J., Gil‐de‐Gómez, L., Rodríguez‐Martín, A., Valentí, M., Payo, B. F., Marín-Muñoz, J., Antúnez, C., Frank, A., Acedo, C., Gracia, L. M., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142925 · Cited by 120
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 117
Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H. J., Soininen, H. S., Aalten, P., Rikkert, M. G. M. O., Verbeek, M. M., Spiru, L., Blennow, K., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291712001870 · Cited by 122
Self-citationSoares, H. D., Chen, Y., Sabbagh, M. N., Rohrer, A., Schrijvers, E. M. C., & Breteler, M. M. B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05066.x · Cited by 112
Self-citationBrain Ventricular Volume and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Ott, B. R., Initiative, T. A. D. N., Cohen, R. A., Gongvatana, A., Okonkwo, O. C., Johanson, C. E., Stopa, E. G., Donahue, J. E., & Silverberg, G. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1406 · Cited by 117
Yang, G., Song, Y.-M., Zhou, X.-Y., Deng, Y.-D., Liu, T., Weng, G., Yu, D., & Pan, S.-Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3728 · Cited by 109
Hong, S., Quintero-Monzon, O., Ostaszewski, B. L., Podlisny, D. R., Cavanaugh, W. T., Yang, T., Holtzman, D. M., Cirrito, J. R., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-11.2011 · Cited by 111
The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment
Tosto, G., Zimmerman, M. E., Hamilton, J. L., Carmichael, O. T., Brickman, A. M., & Initiative, A. D. N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.014 · Cited by 112
Self-citationKorecka, M., Waligórska, T., Figurski, M., Toledo, J. B., Arnold, S. E., Grossman, M., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132489 · Cited by 117
Self-citationBrinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111
Self-citationLiu, Y., Pan, N., Ma, Y., Zhang, S., Guo, W., Haihong, L., Zhou, J., Liu, G., & Gao, M. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31825a674d · Cited by 111
Ewers, M., Brendel, M., Rizk‐Jackson, A., Rominger, A., Bartenstein, P., Schuff, N. W., & Weiner, M. W. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.10.018 · Cited by 116
Fortea, J., Sala‐Llonch, R., Bartrés‐Faz, D., Lladó, A., Solé‐Padullés, C., Bosch, B., Antonell, A., Olives, J., Sánchez‐Valle, R., Molinuevo, J. L., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.017 · Cited by 112
Belloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110
Self-citationAutomated MRI measures predict progression to Alzheimer's disease
Desikan, R. S., Cabral, H., Settecase, F., Hess, C. P., Dillon, W. P., Glastonbury, C. M., Weiner, M. W., Schmansky, N. J., Salat, D. H., & Fischl, B. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.023 · Cited by 112
Forlenza, O. V., Radanovic, M., Talib, L. L., Aprahamian, I., Diniz, B. S., Zetterberg, H., & Gattaz, W. F. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.003 · Cited by 114
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D. A., Carmona‐Iragui, M., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 106
Self-citationKočiš, P., Tolar, M., Yu, Y., Sinko, W., Ray, S. S., Blennow, K., Fillit, H. M., & Hey, J. A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0434-z · Cited by 116
Self-citationInsel, P. S., Mormino, E. C., Aisen, P. S. S., Thompson, W. K., & Donohue, M. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa007 · Cited by 112
Self-citationProgressive supranuclear palsy: Advances in diagnosis and management
Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 118
Gold, B. T. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.12.006 · Cited by 119
Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients
Zetterberg, H., Tullhög, K., Hansson, O., Minthon, L., Londos, E., & Blennow, K. (2010) · European Neurology · doi:10.1159/000311703 · Cited by 108
Self-citationRisk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes
Perret‐Liaudet, A., Pelpel, M., Tholance, Y., Dumont, B., Vanderstichele, H., Zorzi, W., Elmoualij, B., Schraen‐Maschke, S., Moreaud, O., Gabelle, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120361 · Cited by 108
Self-citationAlzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 112
Nogueras‐Ortiz, C. J., Mahairaki, V., Delgado‐Peraza, F., Das, D., Avgerinos, K. I., Eren, E., Hentschel, M. B., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 112
Squitti, R., Ghidoni, R., Siotto, M., Ventriglia, M., Benussi, L., Paterlini, A., Magri, M., Binetti, G. G., Cassetta, E., Caprara, D., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24136 · Cited by 108
Relation-induced multi-modal shared representation learning for Alzheimer’s disease diagnosis
Ning, Z., Xiao, Q., Feng, Q., Chen, W., & Zhang, Y. (2021) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2021.3063150 · Cited by 106
An Efficient Classifier for Alzheimer’s Disease Genes Identification
Xu, L., Liang, G., Liao, C., Chen, G.-D., & Chang, C.-C. (2018) · Molecules · doi:10.3390/molecules23123140 · Cited by 107
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 108
Self-citationLautner, R., Palmqvist, S., Mattsson, N., Andréasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S., Owenius, R., Olsson, B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1060 · Cited by 110
Self-citationAlmeida, R. P., Schultz, S. A., Austin, B. P., Boots, E. A., Dowling, N. M., Gleason, C. E., Bendlin, B. B., Sager, M. A., Hermann, B. P., Zetterberg, H., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0098 · Cited by 107
Gupta, Y., Lee, K. H., Choi, K. Y., Lee, J. J., Kim, B. C., Kwon, G., & Initiative, A. D. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222446 · Cited by 107
Self-citationRutledge, J., Lehallier, B., Zarifkar, P., Losada, P. M., Shahid, M., Western, D., Gorijala, P., Ryman, S. G., Yutsis, M. V., Deutsch, G. K., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02706-0 · Cited by 119
Donovan, N. J., Wadsworth, L. P., Lorius, N., Locascio, J. J., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.006 · Cited by 106
Beckett, L. A., Donohue, M., Wang, C., Aisen, P. S. S., Harvey, D. J., Saito, N. H., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.004 · Cited by 108
Self-citationFluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Self-citationToledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Self-citationPlasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
Lue, L.-F., Sabbagh, M. N., Chiu, M.-J., Jing, N., Snyder, N. L., Schmitz, C., Guerra, A., Belden, C. M., Chen, T.-F., Yang, C.-C., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00226 · Cited by 105
Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 109
Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109
Self-citationBrain Atrophy in Healthy Aging Is Related to CSF Levels of Aβ1-42
Fjell, A. M., Walhovd, K. B., Fennema‐Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., Blennow, K., Brewer, J. B., Dale, A. M., & Initiative, T. A. D. N. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp279 · Cited by 106
Self-citationStomrud, E., Björkqvist, M., Janciauskiene, S. M., Minthon, L., & Hansson, O. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt44 · Cited by 107
Cruchaga, C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.155 · Cited by 103
A Blood Gene Expression Marker of Early Alzheimer's Disease
Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 104
Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI
Sundermann, E. E., Maki, P. M., Biegon, A. R., Lipton, R. B., Mielke, M. M., Machulda, M. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008467 · Cited by 105
Self-citationRelationship of dementia screening tests with biomarkers of Alzheimer's disease
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A., & Morris, J. C. (2010) · Brain · doi:10.1093/brain/awq204 · Cited by 103
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
Self-citationMultimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia
Hu, W. T., McMillan, C. T., Libon, D. J., Leight, S., Forman, M. S., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ed9c52 · Cited by 102
Self-citationVenkatraghavan, V., Bron, E. E., Niessen, W. J., & Klein, S. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.11.024 · Cited by 102
Novel CSF biomarkers for frontotemporal lobar degenerations
Hu, W. T., Chen‐Plotkin, A. S., Grossman, M., Arnold, S. E., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L., Hurtig, H. I., Siderowf, A. D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d78d · Cited by 101
Self-citationClinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions
Gavett, B. E., Cantu, R. C., Shenton, M., Lin, A. P., Nowinski, C. J., McKee, A. C., & Stern, R. A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd477 · Cited by 101
Varatharajah, Y., Ramanan, V. K., Iyer, R. K., Vemuri, P., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R. C., Jack, C. R., Saykin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38793-3 · Cited by 108
Self-citationLeoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.26 · Cited by 116
Self-citation
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
